{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:29:32Z","timestamp":1790710172907,"version":"4.1.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1136\/annrheumdis-2016-210459","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T20:35:13Z","timestamp":1496694913000},"page":"1679-1687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study"],"prefix":"10.1016","volume":"76","clinical-trial-number":[{"clinical-trial-number":"nct01970488","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01970475","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01970488","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02114931","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stanley","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Perez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L","family":"Pablos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Hrycaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Shergy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Primal","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2016-210459_bib1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of Rheumatoid Arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med Overseas Ed"},{"key":"10.1136\/annrheumdis-2016-210459_bib2","series-title":"Humira (adalimumab) injection [prescribing information]","year":"2016"},{"issue":"suppl 10","key":"10.1136\/annrheumdis-2016-210459_bib5","first-page":"S168","article-title":"Costs of tumor necrosis factor blockers per treated rheumatoid arthritis patient using real-world drug data in a us managed care population [abstract]","volume":"64","author":"Schabert","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210459_bib6","doi-asserted-by":"crossref","first-page":"A18","DOI":"10.1016\/j.jval.2011.02.109","article-title":"Php38 utilization, price and spending of anti-tumor necrosis factor biologics in the United States medicaid program","volume":"14","author":"Atzinger","year":"2011","journal-title":"Value in Health"},{"key":"10.1136\/annrheumdis-2016-210459_bib7","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210459_bib8","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210459_bib18","series-title":"INFLECTRA (infliximab-dyyb)","year":"2016"},{"key":"10.1136\/annrheumdis-2016-210459_bib19","series-title":"ERELZI (etanercept-szzs) injection, for subcutaneous use [prescribing information]","year":"2016"},{"key":"10.1136\/annrheumdis-2016-210459_bib20","series-title":"AMJEVITA (adalimumab-atto) injection for subcutaneous use [prescribing information]","year":"2016"},{"key":"10.1136\/annrheumdis-2016-210459_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s40259-016-0184-3","article-title":"Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab","volume":"30","author":"Liu","year":"2016","journal-title":"BioDrugs"},{"key":"10.1136\/annrheumdis-2016-210459_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40259-016-0185-2","article-title":"Demonstration of functional similarity of proposed biosimilar ABP 501 to Adalimumab","volume":"30","author":"Velayudhan","year":"2016","journal-title":"BioDrugs"},{"key":"10.1136\/annrheumdis-2016-210459_bib24","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2015-208914","article-title":"A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab","volume":"76","author":"Kaur","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2016-210459_bib25","article-title":"Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: a randomized, double-blind, multicenter, phase III study","author":"Papp","year":"2017761093","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/annrheumdis-2016-210459_bib26","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2016-210459_bib27","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.4161\/mabs.32114","article-title":"Bioanalytical strategy used in development of pharmacokinetic (PK) methods that support biosimilar programs","volume":"6","author":"Colbert","year":"2014","journal-title":"MAbs"},{"key":"10.1136\/annrheumdis-2016-210459_bib29","series-title":"Guidance for industry: drug-induced livery injury: premarketing clinical evaluation","year":"2009"},{"key":"10.1136\/annrheumdis-2016-210459_bib30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724197877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724197877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2016-210459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T03:43:57Z","timestamp":1739504637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724197877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0003496724197877"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2016-210459","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 \u00a9 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}